<DOC>
	<DOCNO>NCT00568477</DOCNO>
	<brief_summary>To evaluate benefit rituximab patient CAN histologically proven C4d deposit and/or plasma cell and/or B-Lymphocyte ( CD20+ cell ) infiltration graft .</brief_summary>
	<brief_title>Value Rituximab Humoral Chronic Rejection After Renal Transplantation</brief_title>
	<detailed_description>This study prospective , randomize , open , 2-arm , national multi-center study evaluate value rituximab humoral chronic rejection renal transplantation approximately 150-200 patient ( 75-100 patient group ) . All biopsy analyse Prof. Groene ( Heidelberg ) result immediately communicated central manage unit ( Munich ) . Upon receipt , patient biopsy proven CAN C4d+ and/or plasma-cells and/or B-lymphocytes within last 4 week inclusion ( centrally confirm ) , fulfil inclusion/exclusion criterion , randomize 1:1 one 2 group : Arm 1 : Treatment rituximab Arm 2 : Treatment without rituximab Recruitment last approximately one year . All patient treat baseline medication Tacrolimus , MMF , steroid ( optional , dose give study entry ) ACE-inhibitor AT1-receptor-antagonist . A single dose 100 mg Methylprednisolone i.v . give baseline ( day 0 ) group ( rituximab group 30 min start rituximab infusion ) . Each patient follow 1 year within protocol , study visit 1,3,7 14 day ( rituximab group ) , 3 , 6 12 month follow follow-up period 1 year study visit 24 month .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Renal allograft recipient least 1 year transplantation GFR &gt; 25 ml/min x 1,73m2 ( MDRD ) Single organ recipient renal allograft Patients provide informed consent Patients &gt; = 18 year age Patients biopsy proven CAN C4d+ deposit and/or plasmacells and/or Blymphocytes within last 4 week inclusion Patients treat ACE/AT1 Blocker 1 week inclusion Patients suffer HIV infection Patients history Hepatitis B Patients Hepatitis C ( active/chronic ) Patients contraindication use rituximab , leukopenia experience infusionrelated adverse event former antibody treatment Patients show sign acute cellular rejection biopsy Patient malignancy history malignancy within last 5 year , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Patient systemic infection require treatment . Female patient pregnant lactating Patients form substance abuse , psychological illness condition , , opinion investigator , may interfere patient 's ability understand requirement study . Patients proteinuria &gt; 4g/24h Patient unlikely comply visit schedule protocol . Patient simultaneously participate another investigational drug study participate study within 28 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Rituximab , Heemannn</keyword>
</DOC>